Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.

ABSTRACT:

Aims

Several studies reported treatment benefits of tolvaptan in patients with congestive heart failure (CHF). However, the optimal dosage remains unclear. We aimed to compare different dosage of tolvaptan to determine the optimal dosage in terms of the efficacy and safety.

Methods

We searched MEDLINE, PubMed, EMBASE, Cochrane CENTRAL and ClinicalTrials.gov through Aug 31, 2016. Randomized controlled trials (RCTs) comparing tolvaptan of different dosages or to placebo in patients with CHF were included. We used network meta-analysis to look for the optimal dosage in terms of effectiveness and safety. Urine output, body weight change and change in serum sodium were the main outcomes of efficacy. Adverse effects were the secondary outcomes. Quality was assessed by Cochrane ris

SUBMITTER: Wu MY 

PROVIDER: S-EPMC5595312 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature